A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis

SIMPLE SUMMARY: This study is one of the very few phase I trials on intraperitoneal chemotherapy applied as PIPAC. Cisplatin and doxorubicin may be safely used as PIPAC at a dose of 30 mg/m(2) and 6 mg/m(2), respectively; oxaliplatin can be used at an intraperitoneal dose of 135 mg/m(2). No serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Robella, Manuela, De Simone, Michele, Berchialla, Paola, Argenziano, Monica, Borsano, Alice, Ansari, Shoeb, Abollino, Ornella, Ficiarà, Eleonora, Cinquegrana, Armando, Cavalli, Roberta, Vaira, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958944/
https://www.ncbi.nlm.nih.gov/pubmed/33802269
http://dx.doi.org/10.3390/cancers13051060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958944/
https://www.ncbi.nlm.nih.gov/pubmed/33802269
http://dx.doi.org/10.3390/cancers13051060

Ejemplares similares